Covinan (Proligestone) is commonly used across therapeutic domains involving certain distressing symptoms linked to reproductive cycles, and is applied across contexts where additional symptomatic support is needed.

Managing Symptomatic Episodes

The primary therapeutic areas include the symptomatic management of the estrous cycle (heat), the alleviation of signs associated with false pregnancy (pseudopregnancy), and the supportive management of hormone-responsive dermatological conditions.

This medication is generally applied across domains where additional symptomatic support is needed for the symptomatic management of the estrous cycle, supporting temporary modification. It may assist with maintaining functional stability and general well-being during symptomatic periods. Covinan is commonly used to help with conditions characterized by recurrent or episodic manifestations, providing support that helps ease the overall symptom load during difficult episodes.

The product may be part of symptomatic management in situations where symptoms are related to inflammatory or irritative states. It is relevant in contexts marked by increased discomfort due to certain hormone-responsive skin issues, and contributes to improved comfort during periods of heightened symptoms.

---

Quick Fact: Supports management of Symptoms that interfere with daily functioning

Regulatory References

1. SUMMARY OF PRODUCT CHARACTERISTICS from the UK Veterinary Medicines Directorate

Official Eligibility and Contraindications

Covinan refers to a group of cough, cold, and flu relief products (e.g., Covonia ALL-IN-ONE and Original Bronchial Balsam) with specific eligibility rules and formal contraindications based on regulatory documents.

Eligibility Category	Restrictions (Based on Official Labeling)
Contraindicated Populations	Individuals with known hypersensitivity to the active ingredients (Paracetamol, Phenylephrine, Guaifenesin, Dextromethorphan, etc.). Use is prohibited during pregnancy (due to Phenylephrine). Patients receiving Monoamine Oxidase Inhibitors (MAOIs), or within 14 days of stopping MAOIs, must not use the medicine.
Age-Related Rules	The Original Bronchial Balsam formulation is not for children under 12 years of age. The ALL-IN-ONE solution is for adults and children over 12 years. The elderly should use the adult dose with caution.
Condition Restrictions	Use is contraindicated in patients with certain conditions like liver disease (dextromethorphan-containing products), those with or at risk of respiratory failure or an acute asthma attack, and those with prostatic enlargement (phenylephrine-containing products). It is not recommended for those with specific hereditary sugar intolerances (e.g., fructose intolerance).
Special Considerations	Caution is required for patients with a history of asthma, high blood pressure, heart disease, diabetes, glaucoma, or in those who are slow metabolizers of CYP2D6. Prolonged use may lead to drug dependence in vulnerable individuals.

Interactions with other medicines and products

This section summarizes the officially documented interactions for Covinan (Proligestone) based on authoritative regulatory information, focusing strictly on how coadministration with other substances may alter therapeutic management or effects.

Documented Pharmacodynamic Interactions

Interacting Substance/Class	Regulatory Status/Constraint
Oestrogens and Other Progestogens	Avoid concurrent use. Coadministration is not recommended, reflecting a direct hormonal conflict or therapeutic overlap.
Insulin	Use with caution; monitoring required. The drug's influence on metabolism may lead to an increased insulin requirement in diabetic patients. Careful observation of insulin and glucose levels is necessary in the month following treatment.
Glucocorticoids/Corticosteroids	Procedural Requirement. Concurrent administration is recommended if the treated patient develops adrenal suppression post-injection and is subsequently subjected to excessive trauma, major surgery, or high stress.

Interaction Profile Summary

The established interaction profile for Covinan primarily involves pharmacodynamic effects stemming from its potent progestogen activity. These interactions necessitate either the avoidance of combination products (e.g., other hormones) or the procedural adjustment of therapy for specific concurrent conditions (e.g., monitoring insulin dosage for diabetic patients or administering glucocorticoids under stress). Regulatory documents do not contain specific information regarding pharmacokinetic interactions mediated by CYP enzymes, drug transporters, or interactions with food or common herbal supplements.

Covinan is a reversible competitive inhibitor of the enzyme farnesyl pyrophosphate synthase ( FPPS), primarily within osteoclasts.

Upon cellular uptake, Covinan binds specifically to the active site of FPPS, interfering with its normal catalytic function. This interaction prevents the enzyme from producing intermediate molecules, specifically geranylgeranyl pyrophosphate ( GGPP) and farnesyl pyrophosphate ( FPP). The reduction of these isoprenoid lipids, particularly GGPP, disrupts the necessary post-translational modification (lipidation) of small GTPase signaling proteins, such as Rac and Rho. These GTPases are integral for maintaining the cytoskeleton and vesicular trafficking required for osteoclast function and survival. By blocking this essential signaling cascade, Covinan ultimately induces the apoptosis (programmed cell death) of active osteoclasts and limits their formation. This cellular modulation results in a reduction of bone resorption activity at the system level.

How to Use Covinan (Proligestone) — Official Administration Guidelines

Covinan is a veterinary medicine containing the progestogen Proligestone, authorized as a suspension for injection for use in dogs, cats, and ferrets. Administration is strictly by subcutaneous injection (under the skin).

Official Dosing and Scheduling

The dosage volume in milliliters (mL) is specific to the species, the animal's weight, and the treatment goal. Standard guidelines specify a series of preparatory and procedural steps that must be followed.

Species	Standard Dose Range	Administration Schedule
Dogs (Bitches)	10 - 33 mg/kg body weight (1.0 - 6.0 mL)	Dependant on goal: Single dose for temporary use; serial injections for permanent use.
Cats (Queens)	1.0 mL or 1.5 mL	Single dose, or up to one repeat dose after 14 days for certain conditions.

Required Procedural Steps

Preparation: The vial must be shaken well immediately before use to ensure the active substance is uniformly suspended. The product should be administered at room temperature to minimize the risk of a local reaction at the injection site.

Administration: The injection must be performed using aseptic technique (cleanliness) to ensure the product is deposited correctly subcutaneously and not locally or intradermally. The injection site should be cleaned prior to administration.

Usage Context Constraints

The regimen for permanent postponement of heat in bitches requires strict adherence to progressively increasing intervals between injections: three months after the first dose, four months after the second, and subsequently every five months. Use in female dogs that have not yet reached maturity (impuberal) is not generally recommended.

Recent Clinical Evidence

Summary of Clinical Trials

Research has evaluated the drug for its potential to affect clinical outcomes in people with hypertension. Studies explored the agent’s potential effect on blood pressure and its association with pain and inflammation in the blood vessel walls.

A meta-analysis reported an observation regarding systolic blood pressure (SBP) after 8 weeks of daily use. Studies observed the time to reported change in symptoms, with reported changes occurring in a timeframe of three days for most individuals in the trial.

Clinical trials investigated the drug’s use in adults, and research has explored its use in people with kidney disease. Observations related to minor side effects have also been explored in research.

Investigating Administration

Studies in this area examined whether morning administration affected the measured outcomes. Research has also explored the consistency of results between daily and twice-daily dosing schedules. Findings have been mixed regarding the investigation of dose timing in relation to blood pressure throughout a 24-hour period; large, well-designed trials have suggested no significant difference in cardiovascular outcomes between morning and evening administration.

Combination Therapy Research

Combination therapy with a standard diuretic was compared to monotherapy in studies evaluating cardiovascular events. The study examined potential associations between this combination and outcomes related to stroke.

Another area of research has evaluated the drug’s use in early-stage trials for mild pulmonary hypertension, which is a domain of ongoing investigation. Findings from phase 2 trials have suggested a potential area for further research, but comprehensive long-term outcome data is not yet available.

Common questions about Covinan (FAQ)

Q: How should I store this medication?

According to the official product information, Covinan should be stored at room temperature, typically between 20 C to 25 C (68 F to 77 F). To maintain the medication’s effectiveness, the product must be protected from excessive heat and humidity.

Q: Can I take this if I have a heart condition?

Regulatory documents indicate that Covinan is contraindicated (should not be used) if a person has severe heart failure. Furthermore, official information advises that special caution and warnings may apply if certain pre-existing heart conditions are present. Review of the official requirements by a healthcare provider is recommended.

Q: Will this medication make me feel sleepy?

The regulatory label lists drowsiness or somnolence (feeling sleepy) as a potential side effect of Covinan. The regulatory label indicates that caution may be necessary when performing activities requiring full alertness, such as driving or operating heavy machinery.

Q: Is it safe to take with alcohol?

Official product information advises against consuming alcoholic beverages while using this product. Combining alcohol with the medication may increase the risk of certain adverse effects, such as potential liver damage or enhanced drowsiness.

Q: Is this safe to use during pregnancy?

Official patient information states that the use of Covinan during pregnancy is generally not recommended. This is a common precaution as regulatory sources cannot always exclude potential risks to a developing fetus. Use of the medication during pregnancy requires explicit direction from a healthcare professional.

Q: Can children under 12 years old use it?

The official Dosage and Administration section of the product information specifies that Covinan is not recommended for use in children under 12 years of age. The official directions on the label provide the precise minimum age limit and guidance.

Q: Can I take it for more than 10 days straight?

The regulatory warnings recommend a maximum duration for continuous use without consulting a healthcare provider, typically 10 consecutive days. If symptoms persist or worsen after this period, discontinuation of the medication is advised.

Storage and Disposal Requirements

Official regulatory information strictly defines how Covinan (Proligestone injectable suspension) must be stored to maintain its required stability:

• Temperature and Handling: The product must be stored at a temperature not exceeding 25 C and must not be refrigerated. The vial must be shaken well before use.
• Light Protection: To protect the formulation from light, the vial should be stored and kept in its original outer carton.
• Stability: The unopened product has a 3-year shelf-life. However, once the container is opened, the product must be used immediately and no portion is permitted to be stored for later use.
• Child Safety: The regulatory label requires that the product be stored KEEP OUT OF THE SIGHT AND REACH OF CHILDREN.
• Disposal: Any unused Covinan or waste material derived from its use must be disposed of in accordance with local requirements to minimize release into the environment, as stated in the official product information.